Background
Clozapine is an atypical antipsychotic used to treat schizophrenia in patients only after failure of response of other antipsychotic drugs because of its agranulocytosis risk. Because of frequent occurrence of gastrointestinal adverse drug reactions (ADR), proton pump inhibitors (PPIs) are often prescribed in patients exposed to clozapine [1, 2] Clozapine is metabolized mainly through the 1A2 isoenzyme, CYP3A4, only in patients with reduced CYP1A2 activity and moderate contribution of CYP2C19 [3] . Agents that induce or inhibit CYP1A2 may increase or decrease, respectively, the metabolism of clozapine [2] . It is well known that smokers need to increase twofold the dose of clozapine compared with nonsmokers because of CYP1A2 induction by cigarette smoke [2] . We report a case of change in clozapine metabolism after substitution of a racemic PPI omeprazole by its (s)-isomer, esomeprazole, associated with a possible infectious event.
Case report
A nonsmoking 51-year-old woman was treated with clozapine beginning November 2005 for chronic psychosis. Moreover, she received cyamemazine (50 mg/day), fluticasone-salmeterol (125 mg-25 mg, one to four times a day), an estrogen pill (levonorgestrel plus ethinylestradiol), and omeprazole (20 mg/day) for gastrointestinal complaints. The last available plasma level measurement, in May 2009, was normal (clozapine=496 μg/l and desmethylclozapine 302 μg/l, respectively). No abnormal plasma levels of clozapine were emphasized in medical reports during her exposure. In April 2010, she was hospitalized due to exacerbation of psychiatric symptoms (hallucination, agitation,…). At the beginning of hospitalization (second day), clozapine and desmethylclozapine plasma level were normal (312 μg/l and 267 μg/l, respectively) for a daily dose of 300 mg. On 28 April, omeprazole was replaced by esomeprazole, the sole PPI referenced in the drug formulary of the psychiatric hospital. Moreover, a probabilist antibioprophylaxis containing amoxicillin + clavulanic acid was prescribed from 29 April to 6 May because of hyperthermia (38°C) and her history of chronic bronchopneumopathy, without identification of infectious agents. Pharmacokinetic monitoring 2 days after the beginning of this treatment (30 April) showed an increase in clozapine and desmethylclozapine plasma levels (1,237 μg/l and 368 μg/l, respectively). The rise of clozapine plasma levels did not change psychiatric status but led to neutropenia: polynuclear neutrophils (PNN) decreased from 9 g/L to 3 g/L on 3 May. Suspecting an interaction, esomeprazole was stopped on 5 May. Six days later, clozapine and desmethylclozapine plasma levels (312 μg/l and 267 μg/l, respectively) and 
Discussion
The first hypothesis suggested by doctors to explain the rise of clozapine plasma levels was the substitution of omeprazole by esomeprazole, leading to the removal of induction of clozapine metabolism by omeprazole. In fact, both racemic omeprazole and its (s)-isomer, esomeprazole, are metabolized by 2C19, 3A4, and 3A5 isoenzymes and inhibit CYP2C19 activity [4, 5] . However, it seems that omeprazole is the sole drug able to induce CYP1A2 activity, supporting clinical data [6] , whereas drug interaction studies with esomeprazole found no potential interaction with drugs metabolized by CYP1A2, 2A6, 2C9, 2D6, or 2E1 isoenzymes [4] . However, in our case, the effect of removing omeprazole induction was seen rapidly-2 days after change of PPI. This delay was not compatible with those reported for drug induction process depending upon the half-life of the enzyme. Then, another explanation for this variation could be the possible inflammatory states and infections. Some data report that serious respiratory infections could increase clozapine levels. The levels and activity of P450 are altered during infection and inflammation, apparently by cytokine release. [7, 8] In conclusion, in our case, drug interactions and/or infectious episodes could explain the variation of clozapine plasma levels. However, we should emphasize that chemical structure differences between racemic and isomer drugs could have an impact on drug metabolism. These pharmacokinetic particularities should be kept in mind by medical staff, mainly in hospitals, because of frequent substitution of drugs with the same pharmacological profile and indication.
